Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Jerry Radich"'
Autor:
Jerry Radich
Publikováno v:
Haematologica, Vol 107, Iss 12 (2022)
Externí odkaz:
https://doaj.org/article/58270ab1400c44be9e34a6807c172d20
Publikováno v:
Cancer Medicine, Vol 10, Iss 16, Pp 5629-5642 (2021)
Abstract Background Comprehensive molecular and cytogenetic profiling of acute lymphoblastic leukemia (ALL) is important and critical to the current standard of care for patients with B‐acute lymphoblastic leukemia (B‐ALL). Here we propose a rapi
Externí odkaz:
https://doaj.org/article/d669c35621ee4ac09f5fb7c1aef47e29
Publikováno v:
Haematologica, Vol 107, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/ec31812180084ce69cc1b6d79f6f56a5
Autor:
Tomas Radivoyevitch, Brian J. Druker, Jerry Radich, Hagop Kantarjian, Wenlong Tang, Michael J. Hanley, Mingxi M. Song, Timothy Smith, Dean Bottino
Publikováno v:
Blood. 140:6793-6795
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9889d7b05d9beea9176515ef0538d43f
https://doi.org/10.1182/blood-2022-159194
https://doi.org/10.1182/blood-2022-159194
Acute leukemia (AL), a cancer of the blood, has continued high mortality rates despite a plethora of available treatments. Variable prognosis, treatment response and survival are largely based on distinct cytogenetic and molecular aberrations that ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60cfafd87c899fa66d8f71c536dbbc33
https://doi.org/10.1101/2022.06.20.22276664
https://doi.org/10.1101/2022.06.20.22276664
Autor:
Jerry Radich
Publikováno v:
British journal of haematologyReferences. 194(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f43cb559c94f9078117f849e7f3ab120
https://pubmed.ncbi.nlm.nih.gov/34114218
https://pubmed.ncbi.nlm.nih.gov/34114218
Autor:
Melanie Mediavilla-Varela, Alexis M Vistocky, Ehab Atallah, Michael J. Mauro, Jerry Radich, Arielle Baim, Kendra Sweet, Michael Heinrich, James E. Thompson, Kathryn E. Flynn, Javier Pinilla Ibarz, Eva Sahakian, Mei-Jie Zhang
Publikováno v:
Blood. 138:2555-2555
Background: Discontinuation of tyrosine kinase inhibitors (TKIs) is feasible in a subset of CML patients who have maintained a deep molecular response for at least two years. Numerous discontinuation trials have been performed and consistently show a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e75b281868ec6d0a55c3d18828120161
https://doi.org/10.1182/blood-2021-147954
https://doi.org/10.1182/blood-2021-147954
Autor:
Frederick R. Appelbaum, Jerry Radich, Xiaoyu Qu, Yu Wu, Liying Yan, Megan Othus, Fabiana Ostronoff, Elihu H. Estey, Soheil Meshinchi, Jerry Davison, Min Fang, Harry P. Erba
Publikováno v:
Cancer. 123:2472-2481
BACKGROUND Aberrant DNA methylation is known to occur in patients with acute myeloid leukemia (AML), whereas methylation signatures and prognostic markers have been proposed. The objective of the current study was to evaluate all CpG sites of the gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc87dc2591682014e5c3b9986d715e9f
https://doi.org/10.1002/cncr.30626
https://doi.org/10.1002/cncr.30626
Autor:
Dennis Dong Hwan Kim, Jane F. Apperley, Christopher A. Eide, Georgios Nteliopoulos, Sin Tiong Ong, Jerry Radich, Francois-Xavier Mahon, Jorge E. Cortes, Brian J. Druker, Satu Mustjoki, Michael J. Mauro, Charles Chuah, Susan Branford, Carlo Gambacorti-Passerini, Timothy P. Hughes, Thomas Ernst, Dong-Kee Kim, A. Hochhaus
Outcomes for patients with chronic myeloid leukemia (CML) have substantially improved due to advances in drug development and rational treatment intervention strategies. Despite these significant advances there are still unanswered questions on patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c12ae3824a105d89fad1c5496061257
https://hdl.handle.net/11541.2/137800
https://hdl.handle.net/11541.2/137800
Autor:
P. le Coutre, Giuseppe Saglio, Jerry Radich, Bruno Martino, Eibhlin Conneally, Wieslaw Wiktor-Jedrzejczak, Tamás Masszi, Véronique Bédoucha, Andrzej Hellmann, M.T. Gómez Casares, Weiping Deng, Francis J. Giles, Valentín García-Gutiérrez, Nancy Krunic, Norbert Gattermann, Susanne Saussele, Jesper Stentoft, Andreas Hochhaus, David M. Ross, Hans D. Menssen
Publikováno v:
Leukemia
Hochhaus, A, Masszi, T, Giles, F J, Radich, J P, Ross, D M, Gomez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, Garcia-Gutierrez, V, Gattermann, N, Wiktor-Jedrzejczak, W, le Coutre, P D, Martino, B, Saussele, S, Menssen, H D, Deng, W, Krunic, N, Bedoucha, V & Saglio, G 2017, ' Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase : results from the ENESTfreedom study ', Leukemia, vol. 31, no. 7, pp. 1525-1531 . https://doi.org/10.1038/leu.2017.63
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Hochhaus, A, Masszi, T, Giles, F J, Radich, J P, Ross, D M, Gomez Casares, M T, Hellmann, A, Stentoft, J, Conneally, E, Garcia-Gutierrez, V, Gattermann, N, Wiktor-Jedrzejczak, W, le Coutre, P D, Martino, B, Saussele, S, Menssen, H D, Deng, W, Krunic, N, Bedoucha, V & Saglio, G 2017, ' Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase : results from the ENESTfreedom study ', Leukemia, vol. 31, no. 7, pp. 1525-1531 . https://doi.org/10.1038/leu.2017.63
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
The single-arm, phase 2 ENESTfreedom trial assessed the potential for treatment-free remission (TFR; i.e., the ability to maintain a molecular response after stopping therapy) following frontline nilotinib treatment. Patients with Philadelphia chromo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7f978aac8518e358eddf83deebc3149
https://pubmed.ncbi.nlm.nih.gov/28218239
https://pubmed.ncbi.nlm.nih.gov/28218239